GERON CORP (GERN) competitors & alternatives
Health Care · NASDAQ
GERON CORP (GERN)'s top competitors and alternatives — its most similar public companies — include Incyte (INCY), Vertex Pharmaceuticals (VRTX), KARYOPHARM THERAPEUTICS INC (KPTI), KEROS THERAPEUTICS INC (KROS), RIGEL PHARMACEUTICALS INC (RIGL), VOR BIOPHARMA INC (VOR), VANDA PHARMACEUTICALS INC (VNDA), ENLIVEN THERAPEUTICS INC (ELVN), CARIBOU BIOSCIENCES INC (CRBU), DISC MEDICINE INC (IRON), AGIOS PHARMACEUTICALS INC (AGIO) and KURA ONCOLOGY INC (KURA). These are GERON CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GERN competitors & alternatives
-
IncyteINCYHealth Care
A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating…
$115.79 (as of 2026-07-22) · market cap $23.3B
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$472.57 (as of 2026-07-22) · market cap $121.4B
-
KARYOPHARM THERAPEUTICS INCKPTIHealth Care
Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in…
$7.18 (as of 2026-07-22) · market cap $178M
-
KEROS THERAPEUTICS INCKROSHealth Care
Clinical-stage biotech developing TGF-beta-targeting protein therapeutics for rare neuromuscular and hematologic diseases with one Phase 3 program licensed to…
$10.21 (as of 2026-07-22) · market cap $202M
-
RIGEL PHARMACEUTICALS INCRIGLHealth Care
Rigel is a commercial-stage biotech with three FDA-approved, niche oncology/hematology drugs generating strong revenue growth and a clinical pipeline of novel…
$37.80 (as of 2026-07-22) · market cap $714M
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
VANDA PHARMACEUTICALS INCVNDAHealth Care
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in…
$5.35 (as of 2026-07-22) · market cap $329M
-
ENLIVEN THERAPEUTICS INCELVNHealth Care
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing targeted small-molecule inhibitors, with a primary focus on its lead BCR-ABL…
$52.85 (as of 2026-07-22) · market cap $3.8B
-
CARIBOU BIOSCIENCES INCCRBUHealth Care
Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood…
$1.66 (as of 2026-07-22) · market cap $165M
-
DISC MEDICINE INCIRONHealth Care
Disc Medicine is a biopharmaceutical company developing targeted, mechanism-based therapies to treat serious hematologic diseases by modulating heme…
$74.32 (as of 2026-07-22) · market cap $2.8B
-
AGIOS PHARMACEUTICALS INCAGIOHealth Care
A commercial-stage biopharmaceutical company focused on transforming the treatment landscape for rare genetic hematologic diseases through its innovative…
$36.05 (as of 2026-07-22) · market cap $2.2B
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
Not quite? Describe exactly what you want →
Peers are GERON CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: GERON CORP (GERN).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.